Oppenheimer Asset Management Inc. acquired a new stake in Repligen Corporation (NASDAQ:RGEN – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 46,326 shares of the biotechnology company’s stock, valued at approximately $6,321,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its position in shares of Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after purchasing an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC bought a new position in shares of Repligen in the third quarter worth about $368,387,000. Opti Capital Management LP bought a new position in shares of Repligen in the fourth quarter worth about $2,399,209,000. Wasatch Advisors LP increased its stake in Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after buying an additional 346,720 shares during the period. Finally, Maverick Capital Ltd. purchased a new position in Repligen in the 1st quarter worth about $178,946,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the stock. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Evercore restated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. HSBC reduced their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Wells Fargo & Company lifted their price target on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Finally, Canaccord Genuity Group lowered their price target on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $166.43.
Repligen Stock Performance
Shares of Repligen stock opened at $166.83 on Friday. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average price is $142.70 and its 200-day moving average price is $131.32. The firm has a market cap of $9.42 billion, a P/E ratio of 228.53, a P/E/G ratio of 3.04 and a beta of 1.03. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77.
Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period in the prior year, the firm earned $0.26 earnings per share. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts expect that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.
Insider Activity at Repligen
In other news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.60% of the company’s stock.
About Repligen
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
See Also
- Five stocks we like better than Repligen
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
